<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795699</url>
  </required_header>
  <id_info>
    <org_study_id>K-321-301</org_study_id>
    <nct_id>NCT05795699</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)</brief_title>
  <official_title>A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Research Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety and efficacy of K-321 in participants with FECD after&#xD;
      descemetorhexis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2023</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to improvement in best corrected (distance) visual acuity (BCVA) by ETDRS letter score during the first 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in best corrected (distance) visual acuity (BCVA) by ETDRS letter score during the first 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achievement in best corrected (distance) visual acuity (BCVA) by ETDRS letter score during the first 12 weeks</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central corneal ECD at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Central corneal endothelial cell images will be captured by non-contact specular microscopy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fuchs Endothelial Corneal Dystrophy</condition>
  <arm_group>
    <arm_group_label>K-321</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-321 ophthalmic solution four times daily (QID) for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ophthalmic solution QID for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ripasudil</intervention_name>
    <description>K-321 ophthalmic solution</description>
    <arm_group_label>K-321</arm_group_label>
    <other_name>K-321</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo ophthalmic solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is at least 18 years old at the screening visit (Visit 1)&#xD;
&#xD;
          -  Has a diagnosis of FECD at Visit 1&#xD;
&#xD;
          -  Meets all other inclusion criteria outlined in clinical study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is a female patient of childbearing potential and any of the following is true:&#xD;
&#xD;
               1. is pregnant or lactating/breastfeeding, or&#xD;
&#xD;
               2. is not surgically sterile, not post-menopausal (no menses for the previous 12&#xD;
                  months), or not practicing an effective method of birth control as determined by&#xD;
                  the Investigator (eg, oral contraceptives, double barrier methods, hormonal&#xD;
                  injectable or implanted contraceptives, tubal ligation, or partner with&#xD;
                  vasectomy)&#xD;
&#xD;
          -  Has a study eye with a history of cataract surgery within 90 days of Visit 1&#xD;
&#xD;
          -  Meet any other exclusion criteria outlined in clinical study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shona Pendse, MD, MMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Kowa Pharma Development Co.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Director, Clinical Operations</last_name>
    <phone>919-433-1600</phone>
    <email>Clinical@KowaUS.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tauber Eye Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Devers Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 5, 2023</last_update_submitted>
  <last_update_submitted_qc>April 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Dystrophies, Hereditary</mesh_term>
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

